Dr. Aravind Ravikumar, Australia
MBBS, FRACP, FAANMS
Staff Specialist Nuclear Medicine Physician : Department of Cancer Imaging. Peter MacCallum Cancer Centre, Victoria.
Staff Specialist Nuclear Medicine Physician : Department of Nuclear Medicine and Specialised PET Services Queensland, Royal Brisbane and Women’s Hospital (RBWH) Queensland.
Chair of Joint Specialist Advisory Committee (JSAC) in Nuclear Medicine, RACP, Coordinator of advanced training, Joint Specialist Advisory Committee (JSAC) in Nuclear Medicine, RACP, 2011-2012 .Coordinator of the Australia-wide registrar Continuing Assessment
Programme (CAP), 2011-2016 Wide experience in Functional Imaging of Neuroendocrine Tumors using 68Ga-DOTA, F-DOPA and FDG PET imaging. Extensive experience in PRRT of NET .
Chan BA, Sim H-W, Ravi Kumar AS....Wyld D. Comparison of Availability and Utility of Functional Imaging (FI) and Peptide Receptor Radionuclide Therapy (PRRT) in the CommNETS Collaboration (Australia, Canada and New Zealand). ESMO Asia Annual Meeting Singapore 2016. 4. Goodman S, Smith J, Ravi Kumar AS…Burge M. Pretherapy Identification of Patients at Risk of Receiving a High Renal Dose Undergoing Peptide Receptor Radionuclide Therapy. ENETS 13th Annual Conference, Barcelona Spain 2016. 5. Lucas C, Goodman S…Ravi Kumar AS. Dosimetry to Estimate the Effect of Gelofusine® on the Renal Absorbed Dose of Lutetium 177-DOTA-octreotate. ENETS 13th Annual Conference, Barcelona Spain 2016. 6. Lucas CJ, Smith JG, Goodman SJ, Ravi Kumar AS. A case report of yttrium 90 microsphere dosimetry to estimate hepatic tolerance of subsequent lutetium 177- DOTA-octreotate therapy for metastatic neuroendocrine tumour. ASCEPT-MPGPCR Joint Scientific Meeting, Melbourne Australia 2014.